Harlan Krumholz, MD, FACC, JACC Editor-in-Chief and Benjamin M. Scirica, MD, MPH, FACC discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease. Interestingly, while semaglutide did not reduce the incidence of COVID-19, it significantly lowered the rates of severe COVID-related events and deaths in those who contracted the virus. Additionally, semaglutide was associated with a 29% reduction in non-cardiovascular deaths, raising intriguing questions about its broader health benefits beyond weight loss and cardiovascular protection. This groundbreaking study opens new avenues for optimizing overall well-being in patients with cardiometabolic disease.
Related content:
www.jacc.org/d...
www.jacc.org/
#jacc, #jaccjournals, #escCongress
Негізгі бет An Analysis From the SELECT Trial - COVID-19| ESC 2024
Пікірлер